Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

Go back to Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
(NASDAQ: BMEA) Delayed: 0.67 -0.02 (2.9%)
Previous Close $0.69    52 Week High $ 
Open $0.66    52 Week Low $ 
Day High $0.70    P/E N/A 
Day Low $0.66    EPS $ 
Volume 223,073